You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 9,764,011

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,764,011

Title:	Injection paradigm for administration of botulinum toxins
Abstract:	Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
Inventor(s):	Turkel; Catherine C. (Newport Coast, CA), Aurora; Sheena K. (Seattle, WA), Brin; Mitchell F. (Newport Beach, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	15/057,866
Patent Claims:	1. A method for treating or reducing the occurrence of a headache in a patient with chronic migraine headaches, the method comprising: local administration of a botulinum neurotoxin to 31 fixed injection sites across seven head and neck muscles, and optionally up to 8 additional injection sites into three specific muscles, wherein these three muscles are subset of the seven head and neck muscles, to thereby treat or reduce the occurrence of chronic migraine headache in the patient. 2. The method of claim 1, wherein the 31 fixed injection sites across the seven head and neck muscles comprise four injection sites in the frontalis; two injection sites in the corrugator; one injection site in the procerus; six injection sites in the occipitalis; eight injection sites in the temporalis; six injection sites in the trapezius and four injection sites in the paraspinal muscles. 3. The method of claim 1, wherein the 8 additional injection sites into three specific muscles comprise two injection sites in the occipitalis; two injection sites in the temporalis; and four injection sites in the trapezius. 4. The method of claim 1, wherein the botulinum neurotoxin is serotype A. 5. The method of claim 4, wherein the botulinum neurotoxin type A is onabotulinumtoxinA. 6. The method of claim 4, wherein the total amount of botulinum toxin type A administered is from about 155 units to about 195 units of onabotulinumtoxinA. 7. The method of claim 4, wherein the total amount of botulinum toxin type A administered to the 31 injection sites is about 155 units of onabotulinumtoxinA. 8. The method of claim 1, wherein the botulinum toxin is a pure botulinum toxin. 9. The method of claim 8, wherein the botulinum neurotoxin type A is incobotulinumtoxinA. 10. The method of claim 8, wherein the total amount of botulinum toxin type A administered is from about 155 units to about 195 units of incobotulinumtoxinA. 11. The method of claim 8, wherein the total amount of botulinum toxin type A administered to the 31 injection sites is about 155 units of incobotulinumtoxinA. 12. The method of claim 4, wherein the botulinum neurotoxin type A is abobotulinumtoxinA. 13. The method of claim 4, wherein the total amount of botulinum toxin type A administered is from about 310 units to about 975 units of abobotulinumtoxinA. 14. The method of claim 4, wherein the total amount of botulinum toxin type A administered to the 31 injection sites is about 310 units of abobotulinumtoxinA. 15. The method of claim 1, wherein the botulinum neurotoxin is serotype B. 16. The method of claim 1 wherein the botulinum neurotoxin is type E. 17. The method of claim 1, wherein the headache is decreased for at least 12 weeks. 18. The method of claim 1, wherein the administration is by injection. 19. The method of claim 1, wherein the administration is by subcutaneous injection. 20. The method of claim 1, wherein the administration is by intramuscular injection.

Details for Patent 9,764,011

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Allergan, Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	12/09/1991	⤷ Try a Trial	2030-03-30
Allergan, Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	12/09/1991	⤷ Try a Trial	2030-03-30
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	04/29/2009	⤷ Try a Trial	2030-03-30
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	07/30/2010	⤷ Try a Trial	2030-03-30
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	11/20/2015	⤷ Try a Trial	2030-03-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.